STK3
Gene Ontology Biological Process
- apoptotic process [TAS]
- hippo signaling [IDA, TAS]
- intracellular signal transduction [IDA]
- negative regulation of canonical Wnt signaling pathway [IMP]
- positive regulation of apoptotic process [ISS]
- positive regulation of fat cell differentiation [IGI]
- positive regulation of protein binding [IDA]
- positive regulation of protein serine/threonine kinase activity [TAS]
- positive regulation of sequence-specific DNA binding transcription factor activity [IGI]
- protein phosphorylation [IDA]
- protein stabilization [IMP]
- signal transduction [TAS]
- signal transduction by phosphorylation [IBA]
Gene Ontology Molecular Function- ATP binding [IDA]
- magnesium ion binding [IDA]
- protein binding [IPI]
- protein dimerization activity [ISS]
- protein kinase activity [TAS]
- protein serine/threonine kinase activator activity [TAS]
- protein serine/threonine kinase activity [EXP, IDA]
- receptor signaling protein serine/threonine kinase activity [IBA]
- ATP binding [IDA]
- magnesium ion binding [IDA]
- protein binding [IPI]
- protein dimerization activity [ISS]
- protein kinase activity [TAS]
- protein serine/threonine kinase activator activity [TAS]
- protein serine/threonine kinase activity [EXP, IDA]
- receptor signaling protein serine/threonine kinase activity [IBA]
MYCBP2
Gene Ontology Molecular Function
Affinity Capture-Western
An interaction is inferred when a bait protein is affinity captured from cell extracts by either polyclonal antibody or epitope tag and the associated interaction partner identified by Western blot with a specific polyclonal antibody or second epitope tag. This category is also used if an interacting protein is visualized directly by dye stain or radioactivity. Note that this differs from any co-purification experiment involving affinity capture in that the co-purification experiment involves at least one extra purification step to get rid of potential contaminating proteins.
Publication
Proteasomal down-regulation of the proapoptotic MST2 pathway contributes to BRAF inhibitor resistance in melanoma.
The RAS-RAF-MEK-ERK pathway is hyperactivated in most malignant melanomas, and mutations in BRAF or NRAS account for most of these cases. BRAF inhibitors (BRAFi) are highly efficient for treating patients with BRAFV600E mutations, but tumours frequently acquire resistance within a few months. Multiple resistance mechanisms have been identified, due to mutations or network adaptations that revive ERK signalling. We have ... [more]
Throughput
- Low Throughput
Curated By
- BioGRID